Although there were numeric differences in NNH values, these differences did not reach statistical significance, with the exception of a marginal significance for 240 mg galcanezumab (indicating fewer adverse events than placebo) and onabotulinumtoxinA (oBTA, indicating more adverse events than placebo).
← all excerpts
A Risk-Difference Meta-Analysis for the Prophylactic Treatments of Chronic Migraine.
1
—
—